导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.54% | 1592/4773 |
| 近一周 | -1.81% | 749/5462 |
| 近一月 | -2.98% | 1493/5421 |
| 近一季 | -5.29% | 1801/5209 |
| 近半年 | 0.55% | 1143/4920 |
| 近一年 | 6.30% | 1480/4366 |
| 近两年 | 51.72% | 1423/2954 |
| 近三年 | 36.14% | 828/2253 |
| 成立以来 | 108.27% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-1.85% 2520/4961 |
11.93% 2266/5312 |
- - |
- - |
| 2025 | 22.35% 1978/4813 |
-0.61% 2323/3635 |
2.67% 1438/4076 |
18.02% 2363/4524 |
1.59% 1310/4813 |
| 2024 | 16.39% 816/3463 |
4.70% 438/2808 |
-0.27% 724/3014 |
14.47% 1968/3129 |
-2.63% 2148/3463 |
| 2023 | -6.62% 865/2656 |
4.91% 858/2280 |
-3.25% 759/2385 |
-1.73% 571/2515 |
-6.38% 1744/2655 |
| 2022 | -18.16% 670/2207 |
-12.07% 568/1919 |
5.13% 937/2016 |
-12.50% 713/2113 |
1.19% 1354/2208 |
| 2021 | -3.10% 887/1822 |
-1.48% 500/1255 |
4.93% 837/1330 |
-5.07% 774/1466 |
-1.25% 1342/1822 |
| 2020 | 46.44% 210/1250 |
-6.05% 451/1028 |
17.92% 356/1067 |
15.66% 203/1164 |
14.29% 286/1184 |
| 2019 | 36.66% 352/1092 |
26.06% 427/754 |
0.89% 153/804 |
-0.95% 624/850 |
8.49% 311/918 |
| 2018 | -19.85% 182/834 |
- - |
- - |
- - |
-11.18% 256/691 |
| 2017 | 17.81% 218/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 中金沪深300A VS. 长安沪深300非周期A(740101) |